Influence of body mass index on disease severity and treatment outcomes in primary aldosteronism.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Araujo-Castro Marta, Goi Jessica, Burrello Jacopo, Monticone Silvia, Mulatero Paolo, Bersano Elena, Schneider Holger, Johann Petersenn Erik, Zopp Stephanie, Capuzzo Virginia, García Cano Ana María, Mena Ribas Elena, Sanmartín Sánchez Alicia, Martín Rojas-Marcos Patricia, Paja Fano Miguel, Díaz Guardiola Patricia, Rebollo Román Ángel, Rizo Gellida Alicia, González-Boillos Marga, Ruiz-Sanchez Jorge Gabriel, Gómez-Hoyos Emilia, Recasens Mònica, Barahona San Millan Rebeca, Picón César María José, Perdomo Carolina M, Robles Lázaro Cristina, Recio José María, Calatayud María, Gonzalvo Diaz Cesar, Lamas Cristina, Serrano Joaquín, Michalopoulou Theodora, Tenes Rodrigo Susana, Jaén Aguila Fernando, Muñoz Rivas Nuria, Moya Mateo Eva María, García Centero Rogelio, Torres Ana, Gutiérrez-Medina Sonsoles, Adel Gamil Aster, Reincke Martin, Parra Ramírez Paola
Аннотация
METHODS: This international retrospective study included patients diagnosed with PA in Germany, Italy, and Spain. Patients with available BMI, serum potassium, blood pressure, and basal plasma aldosterone concentration at diagnosis were included. PA severity was classified using the Primary Aldosteronism Severity Classification.
RESULTS: A total of 1752 patients were analyzed at baseline; 604 (34.5%) had obesity (BMI ≥30 kg/m2). Patients with obesity were older, more frequently male, and had a higher prevalence of cardiometabolic comorbidities, including type 2 diabetes, cardiovascular disease, left ventricular hypertrophy, and obstructive sleep apnea. PA severity according to the Primary Aldosteronism Severity Classification did not differ significantly between patients with and without obesity; however, the prevalence of severe PA increased progressively across BMI categories (MH test for linear trend: χ2(1) = 3.70, P = .054). Following adrenalectomy, the probability of complete hypertension resolution decreased with increasing BMI, whereas biochemical cure rates were similar. Among patients treated with mineralocorticoid receptor antagonists, obesity was associated with a lower likelihood of complete clinical response, without significant differences in biochemical response.
CONCLUSION: In patients with PA, obesity is associated with a higher burden of cardiometabolic comorbidities and increased prevalence of left ventricular hypertrophy at baseline, as well as with less favorable clinical outcome after both surgical and medical treatment.